Handelsbanken Fonder AB Purchases 32,485 Shares of Hologic, Inc. (NASDAQ:HOLX)

Handelsbanken Fonder AB lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 20.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 190,538 shares of the medical equipment provider’s stock after acquiring an additional 32,485 shares during the quarter. Handelsbanken Fonder AB’s holdings in Hologic were worth $13,614,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. McGlone Suttner Wealth Management Inc. bought a new stake in shares of Hologic during the fourth quarter worth $27,000. Venturi Wealth Management LLC bought a new stake in shares of Hologic during the third quarter worth $29,000. NBC Securities Inc. bought a new stake in shares of Hologic during the third quarter worth $33,000. Deseret Mutual Benefit Administrators increased its holdings in Hologic by 42.2% in the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 155 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its holdings in Hologic by 69.4% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 227 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 1.3 %

HOLX stock opened at $77.19 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The stock has a market capitalization of $18.12 billion, a P/E ratio of 36.58, a P/E/G ratio of 2.58 and a beta of 1.00. The business has a 50-day moving average of $75.87 and a 200-day moving average of $72.69. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. Hologic’s revenue for the quarter was down 5.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.07 earnings per share. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on HOLX. UBS Group upped their price objective on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Raymond James upped their price objective on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Wednesday, April 10th. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $87.00.

Insider Transactions at Hologic

In other news, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at $7,793,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock valued at $2,473,443 over the last three months. Company insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.